|
Deguil J, Ravasi L, Auffret A, Babiloni C, Bartres Faz D, Bragulat V, Cassé-Perrot C, Colavito V, Herrero Ezquerro MT, Lamberty Y, Lanteaume L, Pemberton D, Pifferi F, Richardson JC, Schenker E, Blin O, Tarragon E, Bordet R. Evaluation of symptomatic drug effects in Alzheimer's disease: strategies for prediction of efficacy in humans. Drug Discov Today Technol. 2013 Sep;10(3):e329-42. Review. PubMed PMID: 24179995.
AÑO: 2013
|
24179995
|
Tarragon E., Lopez D., Estrada C., Ana G.C., Schenker E., Pifferi F., Bordet R., Richardson J.C., Herrero M.T. Octodon degus: A model for the cognitive impairment associated with alzheimer's disease. CNS Neuroscience and Therapeutics. September 2013. 19:643-648. 10.1111/cns.12125
AÑO: 2013; IF: 3.784
|
|
Babiloni C, Infarinato F, Aujard F, Bastlund JF, Bentivoglio M, Bertini G, Del Percio C, Fabene PF, Forloni G, Herrero Ezquerro MT, Noè FM, Pifferi F, Ros-Bernal F, Christensen DZ, Dix S, Richardson JC, Lamberty Y, Drinkenburg W, Rossini PM. Effects of pharmacological agents, sleep deprivation, hypoxia and transcranial magnetic stimulation on electroencephalographic rhythms in rodents: towards translational challenge models for drug discovery in Alzheimer's disease. Clin Neurophysiol. 2013 Mar;124(3):437-51. doi: 10.1016/j.clinph.2012.07.023. Review. PubMed PMID: 23040292.
AÑO: 2013; IF: 2.979
|
|
Yuste J.E., Echeverry M.B., Ros-Bernal F., Gomez A., Ros C.M., Campuzano C.M., Fernandez-Villalba E., Herrero M.T. 7-Nitroindazole down-regulates dopamine/DARPP-32 signaling in neostriatal neurons in a rat model of Parkinson's disease. Neuropharmacology. December 2012. 63:1258-1267. 10.1016/j.neuropharm.2012.07.031
AÑO: 2012; IF: 4.114
|
|
Barcia C., Ros C.M., Annese V., Sauvage M.A.C.D., Ros-Bernal F., Gómez A., Yuste J.E., Campuzano C.M., De Pablos V., Fernandez-Villalba E., Herrero M.T. ROCK/Cdc42-mediated microglial motility and gliapse formation lead to phagocytosis of degenerating dopaminergic neurons in vivo. Scientific Reports. 2012. 2. 10.1038/srep00809
AÑO: 2012; IF: 2.927
|